AU9058291A - Composite antibodies of human subgroup IV light chain capable of binding to tag-72 - Google Patents

Composite antibodies of human subgroup IV light chain capable of binding to tag-72

Info

Publication number
AU9058291A
AU9058291A AU90582/91A AU9058291A AU9058291A AU 9058291 A AU9058291 A AU 9058291A AU 90582/91 A AU90582/91 A AU 90582/91A AU 9058291 A AU9058291 A AU 9058291A AU 9058291 A AU9058291 A AU 9058291A
Authority
AU
Australia
Prior art keywords
hum4
antibody
composite
dna
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU90582/91A
Other languages
English (en)
Inventor
Kim S. Johnson
Peter S. Mezes
Ruth A. Richard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Chemical Australia Pty Ltd
Original Assignee
Dow Chemical Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Australia Pty Ltd filed Critical Dow Chemical Australia Pty Ltd
Priority claimed from SG1996004881A external-priority patent/SG55075A1/en
Priority claimed from PCT/AU1991/000583 external-priority patent/WO1993012231A1/en
Publication of AU9058291A publication Critical patent/AU9058291A/en
Priority to AU74089/96A priority Critical patent/AU696627B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU90582/91A 1991-12-13 1991-12-13 Composite antibodies of human subgroup IV light chain capable of binding to tag-72 Abandoned AU9058291A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU74089/96A AU696627B2 (en) 1991-12-13 1996-11-29 Composite antibodies of human subgroup IV light chain capable of binding to TAG-72

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG1996004881A SG55075A1 (en) 1991-12-13 1991-12-13 Composite antibodies of human subgroup iv light chain capable of binding to tag-72
PCT/AU1991/000583 WO1993012231A1 (en) 1991-12-13 1991-12-13 Composite antibodies of human subgroup iv light chain capable of binding to tag-72
CA002121041A CA2121041C (en) 1991-12-13 1991-12-13 Composite antibodies of human subgroup iv light chain capable of binding to tag-72

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU74089/96A Division AU696627B2 (en) 1991-12-13 1996-11-29 Composite antibodies of human subgroup IV light chain capable of binding to TAG-72

Publications (1)

Publication Number Publication Date
AU9058291A true AU9058291A (en) 1993-07-19

Family

ID=25677179

Family Applications (1)

Application Number Title Priority Date Filing Date
AU90582/91A Abandoned AU9058291A (en) 1991-12-13 1991-12-13 Composite antibodies of human subgroup IV light chain capable of binding to tag-72

Country Status (3)

Country Link
JP (1) JPH07501922A (ja)
AU (1) AU9058291A (ja)
CA (1) CA2121041C (ja)

Also Published As

Publication number Publication date
JPH07501922A (ja) 1995-03-02
CA2121041C (en) 2004-08-10
CA2121041A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
US5976845A (en) Composite antibodies of human subgroup IV light chain capable of binding to TAG-72
US6248516B1 (en) Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors
AU662311B2 (en) Recombinant antibodies specific for a growth factor receptor
US6730300B2 (en) Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
EP0365997B1 (en) A novel family of high affinity, modified antibodies for cancer treatment
JP3631750B2 (ja) ヒトｍｄｒ１マルチドラッグ耐性遺伝子産物に対するモノクローナル抗体およびその使用
US5993813A (en) Family of high affinity, modified antibodies for cancer treatment
JPH08501925A (ja) 糖蛋白ｐに対するモノクローナル抗体
US7179899B2 (en) Composite antibodies of humanized human subgroup IV light chain capable of binding to TAG-72
US6207815B1 (en) Family of high affinity, modified antibodies for cancer treatment
EP0618969B1 (en) Composite antibodies of human subgroup iv light chain capable of binding to tag-72
WO1998012227A1 (en) Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US5645817A (en) Granulocyte-binding antibody constructs, their preparation and use
US5849877A (en) Antigen-binding sites of antibody molecules specific for cancer antigens
EP1492819A2 (en) Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
US5811267A (en) Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
AU696627B2 (en) Composite antibodies of human subgroup IV light chain capable of binding to TAG-72
AU9058291A (en) Composite antibodies of human subgroup IV light chain capable of binding to tag-72
JP3045313B2 (ja) Ｔａｇ−７２に結合できるヒトサブグループｉｖ ｌ鎖の複合抗体
US6641999B1 (en) Probing method for identifying antibodies specific for selected antigens
FI103477B (fi) Menetelmä terapeuttisesti käyttökelpoisen vasta-aineen tai vasta-ainef ragmentin valmistamiseksi
NO316023B1 (no) Fremgangsmåte for fremstilling av et terapeutisk aktivt antistoff eller etterapeutisk aktivt fragment derav som er selektive for TAG-72